[1. Tefferi A, Thiele J, Vardiman J. The 2008 World Health Organization Classifi cation System for Myeloproliferative Neoplasms-order out of Chaos. Cancer. 2009:3842-3847.10.1002/cncr.24440]Search in Google Scholar
[2. Vardiman J, Thiele J, Daniel A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.10.1182/blood-2009-03-209262]Search in Google Scholar
[3. Koopmans SM, van Marion AMW, Schouten HC. Myeloproliferative neoplasia: a review of clinical criteria and treatment. Neth J Med. 2012;70(4):159-165.]Search in Google Scholar
[4. Pane F, Intrieri M, Quintarelli C, et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21(56):8652-8667.10.1038/sj.onc.1206094]Search in Google Scholar
[5. McLornan D, Percy M, McMullin M. JAK2V617F: A Single Mutation in the Myeloproliferative Group of Disorders. Ulster Med J. 2006;75(2):112-119.]Search in Google Scholar
[6. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.10.1038/sj.leu.2403135]Search in Google Scholar
[7. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia. 2003;17(12):2474-2486.10.1038/sj.leu.2403136]Search in Google Scholar
[8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.10.1016/S0140-6736(05)71142-9]Search in Google Scholar
[9. Hehlmann R, Grimwade D, Simonsson B, et al. The European LeukemiaNet: achievements and perspectives. Haematologica. 2011;96(1):156-162.10.3324/haematol.2010.032979301278021048032]Search in Google Scholar
[10. Szántó A, Pap Z, Benedek I, et al. Monitoring M-BCR-ABL expression level in CML patients by RQ-PCR: experience of a single Center. Rom J Morphol Embryol. 2013;54(1):37-42.]Search in Google Scholar
[11. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.10.1200/JCO.2009.25.0779497910019884523]Search in Google Scholar
[12. Tefferi A, Vardiman JW. Classifi cation and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.10.1038/sj.leu.240495517882280]Search in Google Scholar
[13. Schnittger S, Bacher U, Eder Ch, et al. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workfl ow. Haematologica. 2012;97(10):1582-1585.10.3324/haematol.2012.064683348756022511494]Search in Google Scholar
[14. Scott ML, Tong W, Ross LL, et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. N Engl J Med. 2007;356(5):459-468.10.1056/NEJMoa065202287383417267906]Search in Google Scholar
[15. Bojko P, Abenhardt W, Schnittger S, Haferlach T. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease. Onkologie. 2009;32(4):191-195.]Search in Google Scholar
[16. Cho YU, Chi HS, Lee EH, et al. Comparison of clinicopathologic fi ndings according to JAK2 V617F mutation in patients with essential thrombocythemia. Int J Hematol. 2009;89(1):39-44.10.1007/s12185-008-0222-019093167]Search in Google Scholar
[17. Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms. Ann Lab Med. 2012;32:385-391.10.3343/alm.2012.32.6.385348693123130336]Search in Google Scholar
[18. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G_T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome- negative CML, and megakaryocytic leukemia. Blood. 2005;106(10): 3370-3373.10.1182/blood-2005-05-1800189506516037387]Search in Google Scholar
[19. Pich A, Riera L, Sismondi F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62(9):798-801.10.1136/jcp.2009.06590419734476]Search in Google Scholar
[20. Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22:1059-1062.10.1038/sj.leu.240499317972958]Search in Google Scholar
[21. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21:1103-1104.10.1038/sj.leu.240459117301812]Search in Google Scholar
[22. Cappetta M, Perez V, Zubillaga MN, et al. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in fi ve patients with myeloproliferative neoplasm at diagnosis. Int J Lab Hematol. 2013;35:e4- e5. 10.1111/ijlh.1201023062104]Search in Google Scholar